@misc{10481/64223,
year = {2020},
month = {9},
url = {http://hdl.handle.net/10481/64223},
abstract = {Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.},
organization = {National Science Center, Poland

	
UMO-2017/26/A/ST5/00363
UMO-2017/26/A/ST5/00364},
publisher = {MDPI},
keywords = {COVID-19},
keywords = {SARS-CoV-2},
keywords = {2019-nCoV},
keywords = {Zn(II) ionophores},
keywords = {Chloroquine},
keywords = {Hydroxychloroquine},
title = {Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?},
doi = {10.3390/ph13090228},
author = {Hecel, Aleksandra and Domínguez Martín, Alicia},
}